# Bristol-Myers Squibb Company (BMY) — Q2-2017 Earnings Results

**Report date:** 2017-07-27 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q2-2017

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Misses on EPS — Stock Down 3.11%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.74 | N/A | -1.36% |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about market conditions affecting performance. They reiterated their focus on future product launches and pipeline strength.

**Key quotes:**

> Management highlighted ongoing challenges in the market.

> They emphasized the importance of pipeline developments moving forward.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a 3.11% decline in stock price. Investors may be reacting to management's cautious tone regarding market challenges and the lack of updated guidance. The focus will likely shift to the company's pipeline and future product launches as key factors for recovery.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q2-2017_